Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.8752W HIGH $6.45
Volume
23.22 K
Value Traded
625.17 K
Short % Float
11.96%
+1.75%Week
-0.95%1 Month
+4.61%3 Month
-7.94%6 Month
-80.55%5 Year
-83.64%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
411.45 M
EPS (TTM)
-2.06
P/E Ratio
-
Ent. Value
191.18 M
Total Shares
80.15 M
Float Shares
63.79 M
Insiders
20.46%
Institutions
71.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AVIR Catalyst Timeline
Dated clinical, regulatory and corporate events for Atea Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Atea Pharmaceuticals, Inc.
321Total events
11Upcoming
78Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Primary Endpoint MetBemnifosbuvirClinical Data
BEM/RZR met primary endpoint of non-inferiority vs SOF/VEL in C-BEYOND
hepatitis C virussource ↗
▲Enrollment CompleteBemnifosbuvirTrial
C-FORWARD fully enrolled with >880 patients
hepatitis C virussource ↗
▲Primary Endpoint MetBemnifosbuvir-RuzasvirClinical Data
C-BEYOND met primary endpoint of non-inferiority vs SOF/VEL
Hepatitis C Virussource ↗
▲Secondary Endpoint DataBemnifosbuvir-RuzasvirClinical Data
C-BEYOND met secondary endpoints including per-protocol analysis
Hepatitis C Virussource ↗
▲Enrollment CompleteBemnifosbuvir-RuzasvirTrial
C-FORWARD fully enrolled with more than 880 patients
Hepatitis C Virussource ↗
▲Trial InitiationAT-587Trial
Initiation of first-in-human Phase 1 clinical trial of AT-587
hepatitis E virus (HEV) infectionsource ↗
▲Primary Endpoint MetBemnifosbuvir-RuzasvirClinical Data
C-BEYOND Phase 3 trial met primary endpoint of non-inferiority vs SOF/VEL
chronic hepatitis C virus (HCV) infectionsource ↗
▲Trial InitiationAT-587Trial
First-in-human Phase 1 trial of AT-587 initiated
chronic hepatitis E virus (HEV) infectionsource ↗
▲Enrollment CompleteBemnifosbuvir-RuzasvirTrial
Completed patient enrollment in Phase 3 C-FORWARD trial
hepatitis C virussource ↗
◆Topline ReadoutBemnifosbuvir-RuzasvirClinical Data
Topline results from C-BEYOND expected mid-year 2026
hepatitis C virussource ↗
◆Trial InitiationAT-587Trial
Anticipates initiating clinical development of AT-587 for HEV in mid-2026
hepatitis E virussource ↗
◆Topline ReadoutBemnifosbuvirClinical Data
Topline results from Phase 3 C-BEYOND trial in North America
Hepatitis C virus (HCV)source ↗
▲Enrollment CompleteBemnifosbuvirTrial
Enrollment completion expected for Phase 3 C-FORWARD trial outside North America
Hepatitis C virus (HCV)source ↗
▲Enrollment CompleteBemnifosbuvir-RuzasvirTrial
C-FORWARD patient enrollment completed
chronic hepatitis C virus (HCV) infectionsource ↗
▲Poster PresentationBemnifosbuvirPresentation
Poster FRI-636: BEM/RZR low potential to inhibit P-gp, BCRP, OATP1B1/3
hepatitis C virussource ↗
▲Poster PresentationAT-587Presentation
Poster TOP-631: Discovery and preclinical profile of AT-587
hepatitis E virussource ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
◆Trial InitiationAT-587Trial
Initiation of Phase 1 clinical program for AT-587
Hepatitis E virus (HEV) infectionsource ↗
◆Topline ReadoutBemnifosbuvir-RuzasvirClinical Data
Topline results expected mid-2026
hepatitis C virussource ↗
◆Enrollment CompleteBemnifosbuvir-RuzasvirTrial
Enrollment completion expected mid-2026
hepatitis C virussource ↗
◆Topline ReadoutBemnifosbuvirClinical Data
Topline results for C-BEYOND Phase 3 trial expected mid-2026
Hepatitis C Virus (HCV)source ↗
▲Enrollment CompleteBemnifosbuvirTrial
Enrollment completion for C-FORWARD Phase 3 trial expected mid-2026
Hepatitis C Virus (HCV)source ↗
◆Enrollment MilestoneBemnifosbuvirTrial
C-FORWARD enrollment expected to complete mid-2026
Hepatitis C Virus (HCV)source ↗
◆Topline ReadoutBemnifosbuvirClinical Data
Topline results from C-BEYOND expected mid-2026
Hepatitis C Virus (HCV)source ↗
●IND SubmissionAT-587IND
IND/CTA enabling studies completion and clinical development start mid-2026
Hepatitis E Virus (HEV)source ↗
◆Quarterly UpdateCorporate
Q4 and Full Year 2025 Financial Results and Business Update Conference Call
▲Poster PresentationAT-587Presentation
Poster presentation of preclinical results for AT-587 and AT-2490 at CROI 2026
Hepatitis E virus (HEV) infectionsource ↗
▲Oral PresentationAT-587Presentation
In vitro results for AT-587 and AT-2490 presented at CROI 2026
Hepatitis E Virus (HEV)source ↗
◆Oral PresentationPresentation
Atea Pharmaceuticals to present at 44th Annual J.P. Morgan Healthcare Conference
▲Development Candidate NominationAT-587Preclinical
Selection of AT-587 as lead product candidate for HEV clinical program
Hepatitis E virus (HEV) infectionsource ↗
▲Oral PresentationAT-587Presentation
Presentation of preclinical data for AT-587 at EASL Congress 2026
hepatitis E virus (HEV) infectionsource ↗
▲Enrollment CompleteBemnifosbuvir-RuzasvirTrial
Completed enrollment in C-BEYOND Phase 3 trial with >880 patients
hepatitis C virussource ↗
▲Enrollment CompleteBemnifosbuvirTrial
C-BEYOND enrollment completed with over 880 patients
Hepatitis C Virus (HCV)source ↗
◆Enrollment CompleteBemnifosbuvirTrial
C-BEYOND enrollment completion expected by end of 2025
Hepatitis C Virus (HCV)source ↗
◆Oral PresentationBemnifosbuvirPresentation
Multiscale Modeling of Phase 2 Results for BEM and RZR Combination
Hepatitis C Virus Infectionsource ↗
◆Poster PresentationBemnifosbuvirPresentation
Resistance Analysis from Phase 2 Study of BEM and RZR
Hepatitis C Virus Infectionsource ↗
●AbstractBemnifosbuvirPresentation
Abstracts accepted for The Liver Meeting 2025
hepatitis C virus (HCV) infectionsource ↗
●Enrollment UpdateBemnifosbuvirTrial
Patient enrollment in global Phase 3 program well under way
hepatitis C virus (HCV) infectionsource ↗
◆Oral PresentationPresentation
Atea management to present at Morgan Stanley 23rd Annual Global Healthcare Conference
▲First Patient DosedBemnifosbuvirTrial
First patient dosed in global Phase 3 C-FORWARD trial evaluating bemnifosbuvir and ruzasvir
hepatitis C virus (HCV)source ↗
●Enrollment UpdateBemnifosbuvirTrial
C-BEYOND currently enrolling patients in US and Canada
hepatitis C virus (HCV)source ↗
Past FDA Catalysts and PDUFA Decisions
How AVIR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-29 | bemnifosbuvir and ruzasvir (BEM/RZR) fixed-dose combination | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C50 / 100
Pipeline Score
$524M
Pipeline Value
Fair Value
Valuation Signal
9
Drugs Scored
1.3x
rNPV / MCap
Top 17%
Micro Cap(rank 113 of 658)
Percentile Rank
Atea Pharmaceuticals, Inc. carries a moderate pipeline score (50/100), with $1.5B risk-adjusted pipeline value, led by Bemnifosbuvir-Ruzasvir in HEPATITIS C VIRUS CHRONIC INFECTION (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bemnifosbuvir-Ruzasvir Small moleculeNCT07037277 | HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 | ACTIVE NOT_RECRUITING | 1,760 | Mar 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every AVIR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lucidi BrunoDirector | Option | 29,600 142,350 held | $0.00 | 06/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AVIR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 1 % (-23.1 %) | 22.39 M | 4.81 M |
AVIR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AVIR ranks across every disease it competes in
Competitive Position is a premium feature
See how AVIR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAVIR News
AVIRAtea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Atea Pharmaceuticals will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. CEO Jean-Pierre Sommadossi and the management team will discuss their advancements in oral antiviral therapeutics. The company is focused on addressing serious viral infections and is currently evaluating a combination treatment for hepatitis C.
Read more →AVIRAtea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals reported positive results from its Phase 3 C-BEYOND trial for BEM/RZR, demonstrating its potential as a leading treatment for chronic hepatitis C virus (HCV). The trial achieved its primary endpoint of non-inferiority compared to existing therapies. Atea is also advancing its Phase 1 trial for AT-587 targeting hepatitis E virus (HEV) and expects additional results from its C-FORWARD trial in early 2027.
Read more →AVIRAtea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
Atea Pharmaceuticals will host a conference call on August 12, 2026, to discuss its financial results for Q2 2026 and provide a business update. The call will be accessible via telephone and audio webcast. Atea is focused on developing oral antiviral therapies, including treatments for hepatitis C and hepatitis E.
Read more →AVIR▼ -6.4%on this news
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Atea Pharmaceuticals announced positive results from its Phase 3 C-BEYOND trial, where the combination of bemnifosbuvir and ruzasvir (BEM/RZR) demonstrated statistical non-inferiority to the standard treatment, sofosbuvir/velpatasvir (SOF/VEL), for chronic hepatitis C virus (HCV) infection. The trial showed high sustained virologic response rates, particularly with an 8-week regimen for patients without cirrhosis. Atea aims to further validate these findings in its upcoming C-FORWARD trial.
Read more →AVIRAtea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral treatment for hepatitis E virus (HEV). This trial aims to evaluate the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers. Given the lack of approved therapies for HEV, this development is significant, particularly for immunocompromised patients at risk of chronic infection.
Read more →AVIRAtea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has completed patient enrollment in its Phase 3 C-FORWARD trial, evaluating bemnifosbuvir and ruzasvir for hepatitis C treatment. Over 880 treatment-naïve patients were enrolled across 17 countries. The trial aims to compare the new regimen against the current standard of care, with topline results expected by year-end 2026.
Read more →AVIRAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Atea Pharmaceuticals presented promising Phase 1 results for its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) at the EASL Congress 2026. The regimen demonstrated a low risk of drug-drug interactions, supporting its use alongside commonly prescribed medications. Additionally, data for AT-587, a potential treatment for hepatitis E virus, showed high antiviral potency and efficacy. These findings suggest a strong potential for BEM/RZR to become a best-in-class option for hepatitis C treatment.
Read more →AVIR▼ -16.9%on this news
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its Q1 2026 financial results, highlighting progress in its Phase 3 trials for Hepatitis C Virus (HCV) and the upcoming initiation of a Phase 1 trial for Hepatitis E Virus (HEV). The company is optimistic about its HCV treatment regimen, which has shown high efficacy in earlier studies. Additionally, Atea's financial standing remains strong with significant cash reserves.
Read more →AVIR▼ -16.9%on this newsshared move
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals announced that three abstracts have been accepted for presentation at the EASL Congress 2026, showcasing advancements in their viral hepatitis pipeline. The presentations will focus on their fixed-dose combination treatment for hepatitis C and preclinical data for AT-587, a candidate for hepatitis E. The company aims to address significant unmet needs in viral hepatitis treatment.
Read more →AVIRAtea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals will host a conference call on May 12, 2026, to discuss its first quarter financial results and provide a business update. The call will be accessible via a live audio webcast and telephone. Atea is focused on developing oral antiviral therapies, with ongoing clinical programs for HCV and HEV.
Read more →AVIR▲ +6.4%on this news· ran to +21% by day 3
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its fourth quarter and full-year financial results for 2025, highlighting advancements in its global Phase 3 program for hepatitis C virus (HCV) treatment. The company is anticipating topline results from two pivotal trials, C-BEYOND and C-FORWARD, in mid-2026 and late 2026, respectively. Atea also introduced a new hepatitis E virus (HEV) program, with a lead candidate, AT-587, expected to enter clinical development by mid-2026. While the company shows strong execution in advancing its HCV program, it faces financial challenges with a notable decrease in cash reserves since last year.
Read more →AVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
Atea Pharmaceuticals will host a conference call on March 5, 2026, to discuss its fourth quarter and full year 2025 financial results. The call will also provide a business update regarding its antiviral therapies. Atea is focused on developing treatments for serious viral diseases and advancing its product pipeline.
Read more →AVIRAtea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Atea Pharmaceuticals announced promising preclinical results for AT-587, a potential first-in-class treatment for Hepatitis E virus (HEV). The results, presented at CROI 2026, showed AT-587's high potency and safety in vitro. The company plans to initiate a Phase 1 clinical program for AT-587 by mid-2026, addressing the urgent need for effective HEV therapies.
Read more →AVIRAtea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026
Atea Pharmaceuticals will outline its 2026 strategic priorities at the upcoming J.P. Morgan Healthcare Conference. The company plans to present topline results from its global Phase 3 C-BEYOND and C-FORWARD trials for its HCV treatment regimen, expected in mid to late 2026. Additionally, Atea will initiate its Phase 1 program for the HEV candidate, AT-587, anticipated for mid-2026. Atea emphasizes its commitment to developing effective antiviral therapies and addressing gaps in the current treatment landscape.
Read more →AVIRAtea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. CEO Jean-Pierre Sommadossi and the management team will present at the event, showcasing their advancements in oral antiviral therapeutics. The company is recognized for addressing serious viral diseases with a robust pipeline built on a proprietary nucleos(t)ide prodrug platform. A live and archived webcast of their presentation will be available through the company’s website.
Read more →AVIRAtea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has completed patient enrollment in the C-BEYOND Phase 3 trial, involving over 880 treatment-naïve patients across the US and Canada. This trial evaluates the efficacy of a fixed-dose combination regimen of bemnifosbuvir and ruzasvir against existing treatments for hepatitis C virus. Topline results are anticipated by mid-2026, marking a significant step in Atea's efforts to enhance HCV treatment options.
Read more →AVIRAtea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO Jean-Pierre Sommadossi and the management team will participate in the 8th Annual Evercore Healthcare Conference. The event is scheduled for December 3, 2025, at 10:00 a.m. ET in Coral Gables, FL. A live webcast and archived version will be available on Atea’s website. Atea is focused on developing oral antiviral therapies, leveraging its proprietary platform to address unmet medical needs in viral infections.
Read more →AVIR▼ -12.6%on this news
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its third quarter 2025 financial results, highlighting progress in its global Phase 3 program for treating Hepatitis C Virus (HCV). The company announced new data supporting the efficacy of bemnifosbuvir and ruzasvir, and introduced a new development program for Hepatitis E Virus (HEV). Patient enrollment for the ongoing trials is on track, with topline results expected in mid-2026.
Read more →AVIRAtea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Atea Pharmaceuticals presented new modeling data at The Liver Meeting 2025, indicating that their fixed-dose combination of bemnifosbuvir and ruzasvir could achieve near-complete inhibition of hepatitis C virus replication. The regimen demonstrated a high sustained virologic response rate of 98% in treatment-adherent patients. The findings support the regimen's potential as a best-in-class, short-duration treatment option for hepatitis C.
Read more →AVIRAtea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Atea Pharmaceuticals will host a conference call on November 12, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025, and provide a business update. The meeting will be available through a live audio webcast and participants can join by telephone. Atea continues to work on antiviral therapies, highlighting its commitment to addressing unmet medical needs in treating serious viral infections.
Read more →About Atea Pharmaceuticals, Inc.
Headquarters225 FRANKLIN STREET, BOSTON, MA, 02110
Founded2012
BIOPHARMAWATCH ELITE PLUS
Trade the next AVIR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime